The immunoresistance problem patients don\'t hear about
Botulinum toxin (Botox, Dysport, Xeomin, and their Korean equivalents) is one of the most widely used cosmetic injectables globally. Patients receiving regular injections for 5+ years occasionally encounter a frustrating problem: the toxin stops working as well, or stops working entirely. The cause is immunoresistance — the body has developed antibodies against the toxin formulation, neutralizing it before it reaches the target muscle.
Approximately 1–5% of long-term Botox users develop measurable immunoresistance. The risk is higher with:
- High doses per session
- Frequent injection intervals (under 12 weeks)
- Higher cumulative total dose over years
- Use of toxins with higher protein content
The medical and aesthetic communities have responded with formulations engineered to reduce immunogenicity. Coretox, developed by Korean manufacturer Medytox, is one of the leading "protein-free" botulinum toxins in this category.
How traditional Botox formulations work
Botulinum toxin in nature exists as a complex — the active 150 kDa neurotoxin surrounded by larger accessory proteins called complexing proteins or hemagglutinins. These proteins protect the toxin in the digestive tract (where it originates) but serve no function once injected. They do, however, present additional antigens to the immune system, increasing the risk of antibody development.
Traditional formulations (Botox, Dysport, Korean Botulax/Nabota) contain the neurotoxin plus its accessory proteins. Modern science recognizes the proteins as unnecessary for therapeutic effect.
The Coretox approach
Coretox removes the accessory proteins, leaving only the 150 kDa core neurotoxin (hence "Core" + tox). The reduced protein load:
- Lower immunogenicity (fewer antigens for immune system)
- Lower risk of antibody development
- Predicted lower long-term resistance rates
- Stabilization through sodium chloride and surfactants (not proteins)
How Coretox compares to other "naked" toxins
Xeomin (Merz, Germany)
The original protein-free toxin. Available globally since 2005. Same protein-removal approach. The longest clinical track record for the "naked toxin" category.
Innotox (Medytox, Korea — earlier product)
Medytox\'s liquid-format toxin. Reduced protein but not fully protein-free. Marketing approval was revoked in 2020 due to manufacturing irregularities — currently not available.
Coretox (Medytox, Korea — newer)
Medytox\'s replacement product. Engineered to be the Korean equivalent of Xeomin. Available in Korean clinics and selectively in international markets.
Daxxify (Revance, US)
Western alternative with a different stabilization approach (peptide-based). Longer duration of action claimed but different mechanism than Coretox.
Clinical performance
- Onset of effect: 3–5 days (comparable to traditional Botox)
- Peak effect: 7–14 days
- Duration: 3–4 months (similar to traditional)
- Efficacy: comparable for cosmetic indications (glabellar lines, crow\'s feet, forehead)
- Safety profile: similar to other toxins at standard doses
Who benefits most from Coretox
- Long-term Botox users (5+ years) wanting to minimize resistance
- Patients receiving frequent high-dose treatments
- Patients with family history of Botox resistance
- Patients requiring therapeutic (not just cosmetic) toxin use long-term
- Anyone planning sustained long-term toxin use over decades
Who can use traditional Botox
- First-time toxin users
- Occasional users (1–2 sessions per year)
- Cosmetic-only use over moderate timeframes (under 10 years)
- Cost-conscious patients (Coretox premium pricing)
Cost in Korea (2026)
- Standard Botulax/Nabota injection: ₩100,000–250,000 per area
- Coretox injection: ₩150,000–350,000 per area (typically 30–50% premium over standard)
- Allergan Botox (imported): ₩300,000–500,000 per area (highest tier)
- Annual cost typical: ₩600,000–2,400,000 depending on toxin and treatment volume
The Medytox controversy and 2026 status
Medytox, Coretox\'s manufacturer, has had documented regulatory issues. In 2020, Korea\'s MFDS revoked Innotox\'s approval after discovering manufacturing irregularities. Coretox is a newer Medytox product with separate approval and improved manufacturing oversight. Patients selecting Coretox should:
- Verify Coretox specifically (not Innotox)
- Confirm MFDS-approved status
- Use clinics that source from verified suppliers
- Be aware of the historical regulatory concerns
Treatment areas for Coretox
Coretox is used for all standard botulinum toxin cosmetic indications:
- Glabellar lines (frown lines between eyebrows)
- Forehead horizontal lines
- Crow\'s feet
- Masseter reduction
- Trapezius reduction
- Chin pebbling (mentalis)
- Lip flip
- Hyperhidrosis (sweating)
The protein-free advantage in long-term use
The clinical evidence for protein-free toxins reducing antibody development is strongest for therapeutic (medical) use of botulinum toxin — patients with cervical dystonia, spasticity, or other neurological conditions requiring high-dose long-term therapy. For cosmetic use at standard doses, the absolute risk reduction is small but real.
For a typical cosmetic patient using 30–60 units 2–3x per year for 20 years, the cumulative antibody development risk shift from 5% to 2% may be meaningful — particularly for younger patients planning sustained long-term use.
Combining Coretox with standard toxins
Some Korean clinics now offer protocols using:
- Coretox for cosmetic areas where movement preservation matters (forehead, brows)
- Standard toxins for areas where full muscle blocking is desired (glabellar, masseter)
- Combined approach minimizes overall protein load while controlling cost
Side effects
Side effects are similar to other botulinum toxins:
- Bruising at injection sites
- Headache for 24–48 hours
- Excess movement reduction (over-correction)
- Eyelid drooping (Botox migration to levator muscle)
- Asymmetric effect
- Rare allergic reactions to formulation
The protein-free formulation may have lower allergic reaction risk, but the difference is small in absolute terms.
Who should NOT use any botulinum toxin
- Pregnancy or breastfeeding
- Myasthenia gravis or other neuromuscular diseases
- Active facial infection at injection sites
- Botulinum toxin allergy (extremely rare)
- Patients with realistic alternative approaches available
How to choose toxin for your needs
- First-time user: standard toxin is appropriate (Coretox premium not justified)
- 5+ year user with sustained efficacy: continue standard toxin unless resistance suspected
- 5+ year user with declining efficacy: consider switching to Coretox or Xeomin
- Patient planning lifetime sustained use: Coretox/Xeomin from start may be wise
- Therapeutic medical use: protein-free strongly favored
Korean clinic landscape
Coretox is offered at most Gangnam dermatology and plastic surgery clinics. Premium pricing reflects the imported-tier positioning. Most clinics also stock traditional Korean toxins (Botulax, Nabota) and offer patient choice. International patients can request Coretox at the time of consultation — supply is reliable in 2026.
Honest framing
Coretox represents real scientific advancement in botulinum toxin formulation, particularly for long-term sustained use. The protein-free approach is validated by Xeomin\'s 20+ year clinical track record. For first-time and occasional users, the cost premium isn\'t justified by clinical benefit. For sustained long-term users (planning 20+ years of use), the immunoresistance protection is meaningful. The Medytox manufacturer has documented regulatory concerns from past products — verify Coretox specifically (not Innotox) and use reputable clinics. For Korean cosmetic patients planning lifetime maintenance treatment, Coretox is a reasonable choice. For occasional users, standard toxins remain appropriate.